Here are the 10-K annual reports from Adaptin Bio Inc (APTN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow APTN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTN filings page.
Adaptin Bio, Inc. filed an Amendment No. 1 to its annual report for the year ended December 31, 2025. The update is narrow and revises Item 15(b) and Exhibit 23.1 to provide an updated consent from WithumSmith+Brown, PC, its independent registered public accounting firm, to reference a company registration statement that was previously omitted.
The company states that no other financial or non-financial information from the original annual report has been changed and that the amendment does not reflect events occurring after the original filing. As of June 11, 2026, Adaptin Bio had 8,903,229 shares of common stock outstanding, and its non‑affiliate equity market value was approximately $9.3 million as of June 30, 2025.
Adaptin Bio, Inc. is an early-stage biopharmaceutical company developing its BRiTE platform to deliver therapeutics across the blood-brain barrier, with lead candidate APTN-101 targeting EGFRvIII-positive glioblastoma and other cancers. The company completed a merger with Unite Acquisition 1 Corp. in February 2025, becoming a public entity.
For the year ended December 31, 2025, Adaptin reported a net loss of $5.17 million and an accumulated deficit of $9.29 million. Cash and cash equivalents were $459,174, leading management to state substantial doubt about its ability to fund operations for the next twelve months without new capital. Operations are funded primarily through private placements and prior bridge notes that converted into equity.
The company holds an exclusive license from Duke University covering its BRiTE technology, owes clinical and commercial milestones totaling up to $11.7 million plus royalties, and relies on contract manufacturers and sponsored research at Duke. As of March 26, 2026, Adaptin had 8,786,229 common shares outstanding and an approximate non-affiliate equity market value of $9.3 million, with no active trading market for its stock.